Compare Hims and Hers Health Inc (HIMS) vs Match Group Inc (MTCH) Price & Performance

Hims & Hers Health stock trades at $31.59, up 6.51% today, showing strong momentum. The technical outlook is bullish, with the price above key moving averages and support at $30. Fundamentally, revenue growth is robust at 40% year-over-year in Q2 2026 (MarketBeat, 2026-08-10), but profitability remains challenged with a net loss margin of -0.56% in 2026. The company raised its annual revenue forecast to $3.1–3.3 billion (WSJ, 2026-08-10), reflecting confidence in subscriber growth and expansion into weight-loss treatments.

The investment outlook is mixed: strong revenue growth and bullish analyst targets near $35.60 offer upside, but high valuation ratios (P/E of 57.14) and recent earnings misses heighten risk. Key risks include margin pressure from GLP-1 investments and ongoing legal investigations. Wall Street sentiment is cautious, with 65% hold ratings, suggesting patience for profitability improvements.

MTCH trades at $37.26, up 1.78% on the day, with a bearish technical signal and neutral oscillators. The stock shows mixed earnings performance, beating Q2 2026 EPS estimates but missing on revenue, as Tinder faces headwinds while Hinge grows. Strong profitability is evident with a 74.8% gross margin and 20.17% net income margin, though high debt levels remain a concern. Recent news highlights institutional buying interest amid ongoing business transformation.

The outlook is cautiously optimistic, supported by a consensus price target of $42.33 (13.6% upside) and no sell ratings. Key opportunities include Hinge's international expansion and Tinder's turnaround potential, but risks involve execution challenges, competitive pressures, and significant leverage. Earnings growth remains the primary catalyst for valuation re-rating.